Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Summary
Melasma is a localized, acquired hyperpigmentary skin disorder characterized by well-defined, light to dark brown patches. Based on clinical practice and extensive literature reports, tranexamic acid and reduced Glutathione (GSH) are both applied in the treatment of melasma, but their water-soluble nature presents challenges for transdermal absorption. Our preliminary basic and clinical research has demonstrated that ultrasound-assisted delivery significantly enhances the absorption of tranexamic acid and other water-soluble components. Its effect on the skin barrier is temporary and reversible. This study aims to evaluate the efficacy and safety of a compound solution (10% tranexamic acid, 2% GSH) delivered via ultrasound for melasma treatment through a split-face controlled trial.
Official title: Clinical Trial on the Efficacy and Safety of Ultrasound-Enhanced Delivery of Compound Tranexamic Acid Solution in the Treatment of Melasma
Key Details
Gender
All
Age Range
20 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2024-10-20
Completion Date
2026-02-25
Last Updated
2025-11-25
Healthy Volunteers
No
Conditions
Interventions
10%TXA+2%Reduced Glutathione applied via ultrasound at 5W/cm² in10min
5w/cm² Ultrasound-assisted topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins
10%TXA+2%Reduced Glutathione applied via ultrasound at 0W/cm² 10min
topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins
Locations (1)
The first Affiliated hospital with Nanjing medical university
Nanjing, Jiangsu, China